Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Latest concepts in the diagnosis of genetic ALL subtypes

ALL Assembly 2018

Published: 18 Oct 2018

Views: 1834

Rating:

Save

Dr Charles Mullighan - St Jude Children's Research Hospital, Memphis, USA

Dr Charles Mullighan talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about Latest concepts in the diagnosis of genetic ALL subtypes.

Dr Mullighan discusses that it is important to identify these new subtypes to determine how well patients respond to therapy but that there are many complications.

He also considers whether or not to carry out a single trial that encompasses most or all subtypes or alternatively a collaborative study where everyone is genotyping with some approach.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

More from ecancer